RIGL vs. MACK, RGLS, VSTM, EBS, VNDA, XOMA, LXRX, IXHL, OMER, and GBIO
Should you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Merrimack Pharmaceuticals (MACK), Regulus Therapeutics (RGLS), Verastem (VSTM), Emergent BioSolutions (EBS), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Lexicon Pharmaceuticals (LXRX), Incannex Healthcare (IXHL), Omeros (OMER), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry.
Merrimack Pharmaceuticals (NASDAQ:MACK) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.
Rigel Pharmaceuticals has a consensus price target of $5.81, indicating a potential upside of 390.51%. Given Merrimack Pharmaceuticals' higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Merrimack Pharmaceuticals.
Merrimack Pharmaceuticals has higher earnings, but lower revenue than Rigel Pharmaceuticals. Merrimack Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than Merrimack Pharmaceuticals. MarketBeat recorded 2 mentions for Rigel Pharmaceuticals and 1 mentions for Merrimack Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.00 beat Merrimack Pharmaceuticals' score of -0.33 indicating that Merrimack Pharmaceuticals is being referred to more favorably in the media.
Merrimack Pharmaceuticals has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500.
Rigel Pharmaceuticals received 50 more outperform votes than Merrimack Pharmaceuticals when rated by MarketBeat users. Likewise, 68.81% of users gave Rigel Pharmaceuticals an outperform vote while only 67.00% of users gave Merrimack Pharmaceuticals an outperform vote.
Merrimack Pharmaceuticals has a net margin of 0.00% compared to Merrimack Pharmaceuticals' net margin of -21.47%. Merrimack Pharmaceuticals' return on equity of 0.00% beat Rigel Pharmaceuticals' return on equity.
64.0% of Merrimack Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 28.9% of Merrimack Pharmaceuticals shares are owned by company insiders. Comparatively, 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Rigel Pharmaceuticals beats Merrimack Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Rigel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rigel Pharmaceuticals Competitors List
Related Companies and Tools
